Oncologic emergency — fever ≥38.3°C in a patient with ANC <500 — requires immediate empiric broad-spectrum antibiotics.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Febrile Neutropenia / Neutropenic Fever outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Free to start · No credit card · Cancel anytime
Risk factors
- Intensive chemotherapy regimens (AML induction, lymphoma R-CHOP-like, stem cell transplant conditioning)
- Prolonged or severe neutropenia (ANC <100 for >7 days)
- Prior episodes of febrile neutropenia
- Age >65, poor performance status
- Mucositis, indwelling central venous catheter
- Comorbidities — diabetes, CKD, COPD, hepatic dysfunction
Pathophysiology
Chemotherapy-induced neutropenia impairs the primary defense against bacterial and fungal pathogens. Loss of mucosal barrier integrity (mucositis) and presence of indwelling devices facilitate translocation of gut flora and skin organisms into the bloodstream. Without neutrophils, infection can progress rapidly to sepsis and septic shock; the classic inflammatory response is blunted, and fever may be the ONLY sign of serious infection.
Clinical presentation
Symptoms
- Fever may be the ONLY symptom — physical findings often blunted by neutropenia
- Rigors or chills
- Localized symptoms (cough, dysuria, abdominal pain, headache, line site pain) often subtle
- Mucositis, perirectal pain
- Hypotension, tachycardia, altered mental status if progressing to septic shock
Signs / physical exam
- Fever (defined above)
- Often LACK of classic findings — pus, abscess formation may not occur without neutrophils
- Careful exam: oropharynx, perianal area, indwelling line/port sites, skin/nails, lungs, abdomen
- Hemodynamic compromise — hypotension, tachycardia
- Erythema/induration at IV/catheter sites
Classic findings
Cancer patient 7-14 days after chemotherapy with isolated fever and no other localizing signs — start empiric antibiotics WITHIN 60 MINUTES of presentation.
Differential diagnosis
- Drug fever — Pattern of fevers with drug administration; eosinophilia; no infectious source — diagnosis of exclusion
- Transfusion reaction — Temporal relationship to blood product; rigors, hypotension, hemolysis labs
- Tumor fever — Lymphoma, leukemia, renal cell carcinoma can produce paraneoplastic fever; pattern of cyclical fevers; diagnosis of exclusion
- Engraftment syndrome / cytokine release syndrome — Peri-engraftment in HSCT or post CAR-T; rash, hypoxia, weight gain
- Venous thromboembolism — Can present with fever; cancer patients at high risk
- Adrenal insufficiency — After prolonged glucocorticoid courses; hypotension, hyponatremia
Diagnostic workup
Diagnostic criteria
Diagnosis is clinical: ANC <500 (or expected fall <500 in 48 h) + fever as defined. Risk stratification by MASCC (Multinational Association for Supportive Care in Cancer) score — score ≥21 indicates low risk and potential for outpatient oral therapy in select patients.
Labs
- CBC with differential — confirm ANC <500
- Blood cultures — ≥2 sets (one from peripheral vein and one from each lumen of indwelling central line)
- BMP, liver enzymes, lactate
- Urinalysis and urine culture
- Other site-specific cultures (sputum, stool, wound, CSF) based on symptoms
- Procalcitonin (variable utility)
- Respiratory viral PCR panel in respiratory symptoms or seasonal context
Imaging
- Chest X-ray (sensitivity reduced without neutrophils — consider CT chest in high-risk or persistent fevers)
- Site-specific imaging — abdominal CT for abdominal pain (typhlitis), sinus CT, brain MRI as indicated
Treatment
First-line
- EMPIRIC IV broad-spectrum antibiotics WITHIN 60 MINUTES of presentation — DO NOT wait for cultures
- Anti-pseudomonal beta-lactam monotherapy (high-risk patients): cefepime, piperacillin-tazobactam, meropenem, or imipenem-cilastatin
- Add vancomycin (or linezolid, daptomycin) if: hemodynamic instability, suspected catheter-related infection, skin/soft tissue infection, pneumonia with severe sepsis, mucositis with prior fluoroquinolone prophylaxis, or known MRSA colonization
- Continue antibiotics until ANC >500 and afebrile ≥48 hours, OR until completion of standard course if specific pathogen/site identified
Low-risk febrile neutropenia (MASCC ≥21, anticipated short neutropenia, clinically stable, no comorbidities, able to take PO, social support)
- Outpatient oral antibiotics — ciprofloxacin PLUS amoxicillin-clavulanate (or moxifloxacin alone)
- Close follow-up within 24-48 h
- Inpatient admission if any deterioration
High-risk febrile neutropenia (MASCC <21, AML/HSCT, prolonged neutropenia, hemodynamically unstable, comorbidities)
- Hospital admission, IV antibiotics
- Cefepime or piperacillin-tazobactam or carbapenem
- Add vancomycin if indicated (see above)
- G-CSF support (filgrastim, pegfilgrastim) for prolonged or severe neutropenia per ASCO guidelines
Persistent fever ≥4-7 days on broad-spectrum antibiotics
- Empiric antifungal coverage — echinocandin (caspofungin, micafungin, anidulafungin), liposomal amphotericin B, or voriconazole
- CT chest, sinus imaging, fungal markers (galactomannan, beta-D-glucan)
- Reassess for occult source — abscess, line infection (consider line removal), C. difficile, viral reactivation (CMV, HSV)
Septic shock
- ICU admission
- Broaden coverage to include MRSA, Pseudomonas, and consider empiric antifungal early
- Fluid resuscitation, vasopressors, source control
- Hydrocortisone for refractory shock
Second-line / adjunct
- Granulocyte colony-stimulating factors (filgrastim, pegfilgrastim) — primary prophylaxis when chemotherapy regimen has FN risk >20%; secondary prophylaxis after prior FN episode
- Fluoroquinolone prophylaxis (levofloxacin, ciprofloxacin) during prolonged severe neutropenia (controversial — resistance concerns)
- Posaconazole prophylaxis for AML induction/consolidation and high-risk HSCT to prevent invasive aspergillosis
Complications
- Septic shock and multi-organ failure
- Bacteremia, fungemia
- Invasive fungal infections (Candida, Aspergillus)
- Clostridioides difficile colitis
- Neutropenic enterocolitis (typhlitis) — Bacteroides, Clostridium, Pseudomonas; cecal pain, perforation risk
- Catheter-related bloodstream infection
- Treatment delays in cancer therapy from infection
- Mortality 5-50% depending on risk strata and source
PANCE pearls
- Door-to-antibiotic time <60 minutes is the single most important quality metric — every hour delay increases mortality.
- ABSENCE of pus or local inflammation does NOT exclude serious infection in neutropenic patients — neutrophils make pus.
- MASCC score ≥21 identifies low-risk patients who may be candidates for oral outpatient therapy (ciprofloxacin + amoxicillin-clavulanate) with close follow-up.
- Always add vancomycin in hemodynamically unstable patients, suspected catheter infection, or mucositis with fluoroquinolone prophylaxis — but de-escalate when no gram-positive pathogen identified at 48-72 h.
- Persistent fever ≥4-7 days on broad-spectrum antibiotics → add empiric antifungal coverage (echinocandin or liposomal amphotericin).
- Pegfilgrastim is given as a single dose ≥24 hours after chemotherapy completion; do NOT give within 14 days before next chemotherapy cycle.
- Typhlitis (neutropenic enterocolitis) classically presents with RLQ pain, fever, diarrhea in a neutropenic patient — treat with broad-spectrum antibiotics, bowel rest, and surgical consultation.
References
- IDSA 2010 (updated) — Freifeld AG et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by IDSA. Clin Infect Dis 2011; 52:e56-93.
- ASCO/IDSA 2018 — Taplitz RA et al. Outpatient management of fever and neutropenia in adults treated for malignancy: ASCO/IDSA Clinical Practice Guideline Update. J Clin Oncol 2018.
- MASCC Score — Klastersky J et al. The Multinational Association for Supportive Care in Cancer risk index. J Clin Oncol 2000; 18:3038-3051.
- NCCN — NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections.
Practice Hematology questions on FirstPassPA
Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free →
Browse all 514 diagnoses